Recently, inhibitors of TGFβ (1D11) [69], PDGF (Nintedanib) [20], AKT (triciribine) [42], galectin-3 (TD139) [70], LPA-1 (AM966) [40], and LOXL2 (AB0023) [56] have shown promising and beneficial effects in rodent models of lung fibrosis. The gene discussed is LOXL2; the disease is pulmonary fibrosis.